RedHill Biopharma secures worldwide RHB-102 rights

RedHill says it will continue late-stage development of RHB-102 for oncology support and GI indications while exploring potential partnerships.

Rhea-AI Filing Summary

RedHill Biopharma Ltd. regained the ex-North America rights to RHB-102 through a mutual agreement with Hyloris Pharmaceuticals SA to terminate the License & Development Agreement, effective October 15, 2026. Hyloris agreed to pay RedHill a one-time $200,000 break-up fee.

The terminated agreement covered exclusive rights to RHB-102 across all indications and territories outside North America. RedHill now has full worldwide rights to the once-daily, proprietary, bimodal extended-release oral tablet formulation of ondansetron, a 5-HT3 antagonist. The company says it continues late-stage development for oncology support and GI indications, including GLP-1/GIP-associated GI intolerance, and is exploring potential partnerships.

Key Figures

One-time break-up fee: $200,000 Effective termination date: October 15, 2026 Agreement date: February 24, 2025

3 metrics

One-time break-up fee $200,000 Hyloris agreed to pay RedHill under the mutual termination agreement.

Effective termination date October 15, 2026 Date the License & Development Agreement was effectively terminated.

Agreement date February 24, 2025 Date of the License & Development Agreement.

Key Terms

bimodal extended-release oral tablet formulation, 5-HT3 antagonist, GLP-1/GIP-associated GI intolerance

3 terms

bimodal extended-release oral tablet formulation medical

"once-daily, proprietary, bimodal extended-release oral tablet formulation"

5-HT3 antagonist medical

"ondansetron, a 5-HT3 antagonist"

A 5-HT3 antagonist is a drug that blocks a specific serotonin receptor on nerves in the gut and brain, which stops the signals that cause nausea and vomiting—think of it as silencing an alarm bell that tells your body to feel sick. It matters to investors because these medicines treat common, recurring problems (for example after chemotherapy or surgery), so regulatory approvals, patent protection, safety data and market share can meaningfully affect a company’s sales and valuation.

GLP-1/GIP-associated GI intolerance medical

"including GLP-1/GIP-associated GI intolerance"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much will RDHL receive from Hyloris for ending the RHB-102 agreement?

Hyloris agreed to pay RedHill a one-time $200,000 break-up fee under the parties’ mutual agreement.

When did the RDHL RHB-102 license agreement terminate?

The agreement was effectively terminated on October 15, 2026. It was dated February 24, 2025.

What RHB-102 rights did RDHL regain?

RedHill regained the ex-North America rights covering all indications and territories outside North America, giving the company full worldwide rights to RHB-102.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/21/2026 - 07:00 AM EDT Accepted by SEC EDGAR 10/21/2026 - 07:00 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of October 2026
Commission File No.:001-35773

REDHILL BIOPHARMA LTD. 

(Translation of registrant’s name into English)

21 Ha’arba’a Street, Tel Aviv, 6473921, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. 

Form 20-F ☒       Form 40-F ☐

RedHill Biopharma Ltd. (the “Company”) announced today that it has regained the ex-North America rights to RHB-102 through a mutual agreement with Hyloris Pharmaceuticals SA (“Hyloris”) for the termination of the License & Development Agreement relating to the exclusive rights to RHB-102 across all indications and territories outside of North America (the “License Agreement”).

Under the parties’ mutual agreement, the License Agreement, dated February 24, 2025, has been effectively terminated on October 15, 2026, and Hyloris agreed to pay the Company a one-time break-up fee in the amount of $200,000. The termination of the License Agreement returns to RedHill all ex-North America rights to RHB-102, a once-daily, proprietary, bimodal extended-release oral tablet formulation of ondansetron, a 5-HT3 antagonist. With full worldwide rights to RHB-102, the Company continues its late-stage development for oncology support and GI indications, including GLP-1/GIP-associated GI intolerance, and proceeds with exploring potential partnerships.

This Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File No. 333-232776), on March 25, 2021 (File No. 333-254692), on May 3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099), on June 27, 2022 (File No. 333-265845), on June 29, 2023 (File No. 333-273001), on June 20, 2024 (File No. 333-280327), on March 25, 2025 (File No. 333-286082) and on January 22, 2026 (File No. 333-292879), and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on March 30, 2021 (File No. 333-254848), on August 4, 2023 (File No. 333-273709), October 13, 2023 (File No. 333-274957), as amended, on August 9, 2024 (File No. 333-281417) and on July 2, 2026 (File No. 333-297223).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	REDHILL BIOPHARMA LTD.
	(the “Registrant”)
Date: October 21, 2026	By:	/s/ Dror Ben-Asher
	Name:	Dror Ben-Asher
	Title:	Chief Executive Officer